Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1038/355103c0 | DOI Listing |
Retin Cases Brief Rep
December 2024
Casey Eye Institute, Oregon Health & Science University, Portland, OR.
Purpose: To describe two cases of pediatric patients with Coats disease who developed nerve fiber layer (NFL) schisis.
Methods: Observational case series.
Results: Two male pediatric patients, ages 2 and 14, who were being treated for Coats disease were found to have NFL schisis on optical coherence tomography.
Elife
April 2024
Department of Psychiatry, Yale University School of Medicine, New Haven, United States.
Background: Ketamine has emerged as one of the most promising therapies for treatment-resistant depression. However, inter-individual variability in response to ketamine is still not well understood and it is unclear how ketamine's molecular mechanisms connect to its neural and behavioral effects.
Methods: We conducted a single-blind placebo-controlled study, with participants blinded to their treatment condition.
Health Promot Chronic Dis Prev Can
March 2024
Public Health Agency of Canada, Ottawa, Ontario, Canada.
Osteoarthr Cartil Open
December 2023
Aging and Metabolism Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, 73104, USA.
Objective: To develop an imaging mass cytometry method for identifying complex cell phenotypes, inter-cellular interactions, and population changes in the synovium and infrapatellar fat pad (IFP) of the mouse knee following a non-invasive compression injury.
Design: Fifteen male C57BL/6 mice were fed a high-fat diet for 8 weeks prior to random assignment to sham, 0.88 mm, or 1.
Antib Ther
October 2023
Max Planck Bristol Centre for Minimal Biology, University of Bristol, Bristol BS8 1TS, UK.
Background: Due to COVID-19, pandemic preparedness emerges as a key imperative, necessitating new approaches to accelerate development of reagents against infectious pathogens.
Methods: Here, we developed an integrated approach combining synthetic, computational and structural methods with antibody selection and immunization to design, produce and validate nature-inspired nanoparticle-based reagents against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
Results: Our approach resulted in two innovations: (i) a thermostable nasal vaccine called ADDoCoV, displaying multiple copies of a SARS-CoV-2 receptor binding motif derived epitope and (ii) a multivalent nanoparticle superbinder, called Gigabody, against SARS-CoV-2 including immune-evasive variants of concern (VOCs).
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!